Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

4(44%)

Results Posted

33%(1 trials)

Terminated

1(11%)

Phase Distribution

Ph phase_2

56%

Ph phase_1

44%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

4(44.4%)

Phase 2Efficacy & side effects

5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(3)

Terminated(1)

Other(1)

Detailed Status

Completed3

Active, not recruiting3

Terminated1

Recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (44.4%)

Phase 25 (55.6%)

Trials by Status

terminated111%

recruiting111%

completed333%

unknown111%

active_not_recruiting333%

Recent Activity

4 active trials

Showing 5 of 9

completedphase_2

DPX-Survivac and Checkpoint Inhibitor in DLBCL

NCT03349450

active_not_recruitingphase_1

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

NCT04895761

active_not_recruitingphase_2

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT03029403

recruitingphase_2

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04920617

active_not_recruitingphase_2

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

NCT03836352

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT03349450Phase 2

DPX-Survivac and Checkpoint Inhibitor in DLBCL

Completed

NCT04895761Phase 1

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Active Not Recruiting

NCT03029403Phase 2

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Active Not Recruiting

NCT04920617Phase 2

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

NCT03836352Phase 2

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Active Not Recruiting

NCT02323230Phase 2

A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL

Terminated

NCT02785250Phase 1

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Unknown

NCT03332576Phase 1

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Completed

NCT01416038Phase 1

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer